Posts by: Joana Carvalho

Joana Carvalho

Joana holds a BSc in Biology, a MSc in Evolutionary and Developmental Biology and a PhD in Biomedical Sciences from Universidade de Lisboa, Portugal. Her work has been focused on the impact of non-canonical Wnt signaling in the collective behavior of endothelial cells — cells that made up the lining of blood vessels — found in the umbilical cord of newborns.

November 8, 2019November 8, 2019

Endoscopy Given IBD Patients Within 6 Months of Starting Biologic May Limit Complications, Study Says

News

An GI tract examination by endoscopy given within six months of starting treatment with a biologic may lessen the risk of complications in people with inflammatory bowel disease (IBD), a study found. ... Read more

October 21, 2019October 21, 2019

Pediatric-onset IBD Patients Experience More Severe Disease Than Those Diagnosed as Adults, Population-Based Study Says

News

Patients whose symptoms of inflammatory bowel disease (IBD) first appeared during their childhood usually experience more severe disease compared with those whose symptoms started later in adulthood, a study has ... Read more

October 16, 2019October 16, 2019

Caregivers of People Living with IBD Need Better Support, National Survey Finds

News

Results from a national survey highlight the heavy burden inflammatory bowel disease (IBD) places on patients’ family and friends, and the need for new strategies to provide better support to ... Read more

September 20, 2019September 20, 2019

Innovation Pharma Planning 1st Clinical Trial of Oral Brilacidin as Potential Ulcerative Colitis Treatment

News

Innovation Pharmaceuticals is planning a first clinical trial of an oral formulation of Brilacidin as a treatment for ulcerative colitis (UC), one of the most common types of inflammatory bowel disease (IBD). Brilacidin ... Read more

September 6, 2019September 6, 2019

Stelara Approved to Treat Moderate to Severe Ulcerative Colitis in Europe

News

The European Commission (EC) has approved Stelara (ustekinumab) to treat moderately to severely active ulcerative colitis (UC) in adults who are either not responding to, or are intolerant of, standard ... Read more

August 12, 2019August 12, 2019

IBD Patients at Higher Risk of Developing Type 2 Diabetes, Study in Denmark Suggests

News

Patients with inflammatory bowel disease (IBD) are at higher risk of developing type 2 diabetes, compared with the general population, according to a study conducted in Denmark. The study, “Inflammatory ... Read more

August 9, 2019August 9, 2019

NP-178 Becomes Algernon’s Lead Candidate for Treating IBD

News

NP-178 (emoxypine), an oral small molecule being repurposed by Algernon Pharmaceuticals, has become the company’s lead candidate to treat inflammatory bowel disease (IBD). Emoxypine is one of the most commercialized generic ... Read more

July 2, 2019July 2, 2019

Costs of Care for Crohn’s, UC, Have Increased Over Last Five Years in US, Study Says

News

The costs of care for people with inflammatory bowel disease (IBD) living in the U.S. have steadily increased over the last five years, primarily due to the high price tag ... Read more

July 1, 2019July 1, 2019

Therapy Candidate IMU-838 Shows Strong Activity in Preclinical Models of UC, Immunic Announces

News

IMU-838, Immunic Therapeutics‘ lead therapy candidate for the treatment of ulcerative colitis (UC) and relapsing-remitting multiple sclerosis (RRMS), shows strong activity in cellular and animal models of disease, preclinical studies ... Read more

June 24, 2019June 24, 2019

Phase 2 Trials Begin Dosing Patients with SHR0302, Reistone’s Investigational JAK1 Inhibitor

News

The first patients with ulcerative colitis (UC) and Crohn’s disease (CD) have been dosed in two Phase 2 trials assessing the effects of SHR0302, Reistone Biopharma‘s investigational drug for the ... Read more